智通财经APP讯，东瑞制药(02348)发布截至2025年12月31日止年度业绩，该集团取得收入12.31亿元(人民币，下同)，同比增长16.1%;母公司拥有人应占溢利2.14亿元，同比减少62.1%;每股基本盈利0.14元。拟派发末期股息每股为港币0.048元
公告称，母公司拥有人应占溢利约人民币2.14亿元(2024年：人民币5.65亿元)，比2024年减少62.1%。因2024年母公司拥有人应占溢利含出售于集团账面值为零元的35%康融东方(广东)有限公司股权取得净收益约人民币2.78亿元(税前人民币2.87亿元)及善丰路厂区设备验证政府补助净收益约人民币8929.2万元 (税前人民币1.05亿元)所致;如撇除以上非经常性溢利约人民币3.67亿元及出售股权前需分担的康融东方亏损人民币369.6万元因素，2024年母公司拥有人经营性溢利为人民币2.02亿元，则2025年较2024年增加6.1%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.